{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:11:18Z","timestamp":1787821878252,"version":"build-2784847793"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.amjmed.2024.09.027","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T02:24:49Z","timestamp":1727403889000},"page":"416-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chlorthalidone as Secondary Treatment in HFpEF?"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7764-5526","authenticated-orcid":false,"given":"Daniel M.","family":"Gelfman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2024.09.027_bib0001","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2024.09.027_bib0002","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1001\/jamacardio.2018.3957","volume":"3","author":"Srivastava","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.amjmed.2024.09.027_bib0003","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jchf.2023.03.011","article-title":"How to manage heart failure with preserved ejection fraction: practical guidance for clinicians","volume":"11","author":"Desai","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"10","key":"10.1016\/j.amjmed.2024.09.027_bib0004","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.amjmed.2024.09.027_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080","article-title":"Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER trial","volume":"15","author":"Peikert","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"16","key":"10.1016\/j.amjmed.2024.09.027_bib0006","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.amjmed.2024.09.027_bib0007","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.amjmed.2024.09.027_bib0008","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2024.09.027_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2024.07.033","article-title":"Do patients who are over 60, obese, with atrial fibrillation, also have HFpEF?","author":"Gelfman","year":"2024","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2024.09.027_bib0010","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.114.05122","article-title":"Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality","volume":"65","author":"Olde Engberink","year":"2015","journal-title":"Hypertension"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324006193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324006193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T12:48:46Z","timestamp":1753361326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934324006193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0002934324006193"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.09.027","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chlorthalidone as Secondary Treatment in HFpEF?","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}